annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 17A A phase II study of VEGF trap (aflibercept) in patients with radioactive
iodine-refractory, positron emission tomography (PET) positive thyroid
carcinoma. (Abstract #5587)
E. J. Sherman, A. L. Ho, S. Haque, R. A. Ghossein, D. M. Lisa, H. Schöder,
M. S. Baum, A. R. Shaha, R. M. Tuttle, D. G. Pfister
Brd. 17B Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer
(ATC) in the United States: A period prevalence SEER database study
1973–2006. (Abstract #5588)
A. M. Hossain, R. N. Rahman, G. Nagaiah, R. Altaha, S. C. Remick
Brd. 17C Combination therapy with sunitinib and bortezomib in adult patients with
radioiodine refractory thyroid cancer. (Abstract #5589)
R. D. Harvey, J. S. Kauh, S. S. Ramalingam, C. M. Lewis, Z. Chen, S. Lonial,
I. C. Blount, D. M. Shin, F. R. Khuri, T. K. Owonikoko
Brd. 17D Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): A
compassionate use program. (Abstract #5590)
J. Capdevila, L. Iglesias, I. Halperin, A. Segura, M. Vaz, J. Corral, J. J. Grau,
G. Obiols, R. Hitt, J. Tabernero
Brd. 17E Intensity-modulated radiation therapy combined with concurrent and
adjuvant chemotherapy in anaplastic thyroid carcinoma: A single-institution
study. (Abstract #5591)
K. C. Bible, J. R. Molina, J. C. Kasperbauer, R. V. Lloyd, B. McIver, J. C. Morris III,
I. D. Hay, V. Suman, R. C. Smallridge, R. L. Foote
Brd. 17F Use of cystatin C as a biomarker for glomerular filtration rate in patients with
head and neck cancer receiving cisplatin-based chemotherapy.
(Abstract #5592)
E. Boelke, G. Schieren, W. Budach, C. Matuschek, M. Peiper, S. Gripp,
G. Steinbach, M. Pelzer, C. Antke, D. Hermsen
Brd. 17G Effects of aprepitant use in patients (pts) with locally advanced squamous
cell carcinoma of the head and neck (LA SCCHN) treated with high-dose
cisplatin and radiation (RT). (Abstract #5593)
M. Ong, J. Martin, L. Sax, D. S. Ernst, E. Winquist
Brd. 17H Prognostic significance of epithelitis by concurrent cetuximab and
radiotherapy (RT) for locally advanced head and neck squamous cell
carcinoma (HNSCC) patients (Pts). (Abstract #5594)
J. J. Grau, A. Tagliapietra, E. Verger, M. Caballero, C. Muñoz, L. Alos
Brd. 18A Economic burden of resected squamous cell carcinoma of the head and neck
(SCCHN) in a U.S.-managed care population. (Abstract #5595)
B. Chastek, M. Amonkar, N. Samant
Brd. 18B Survival from head and neck cancers based on socioeconomic status in
Asians. (Abstract #5596)
K. P. Chu, S. J. Shema, S. Wu, S. L. Gomez, E. T. Chang, Q. Le
Brd. 18C Stress and depression in head and neck cancer patients by primary surgery
versus primary radiotherapy treatment modality. (Abstract #5597)
C. A. Jensen, J. J. Hu, L. D. Case, J. D. Browne, J. Gilbert, J. Metzner-Sidurski,
E. Franzmann, B. Frizzell, C. Schneider, E. G. Shaw
Brd. 18D Comparison of quality of lives between voice-rehabilitated and
nonrehabilitated laryngectomees in a developing world community.
(Abstract #5598)
B. T. Varghese, A. Mathew, P. Sebastian
Brd. 18E Do the treatment outcome priorities of head and neck cancer patients change
after undergoing radiation treatment? (Abstract #5599)
H. Badr, D. I. Rosenthal, K. Milbury, A. S. Garden, S. J. Frank, G. B. Gunn,
C. S. Cleeland, E. R. Gritz
206